Cancer groups have reacted negatively to an announcement from the Centers for Medicare & Medicaid Services (CMS) about allowing Medicare Advantage plans to use a “step therapy” approach to Part B drugs. The policy is part of an effort to rein in prescription drug costs. Read the full article on Medscape here.